From Name:
From Email:
To Name:
To Email:

Optional Message:


Dexpramipexole fails in ALS

from Medscape

Biogen Idec reports that topline results of a phase 3 trial investigating dexpramipexole in patients with amyotrophic lateral sclerosis failed to show a benefit on primary or secondary outcomes. "Based on these results, Biogen Idec will discontinue development of dexpramipexole in ALS," a statement from the company said. more


Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063